Dimitrios S Papadogias, Polyzois Makras, Gregory A Kaltsas, John P Monson
Until the last decade, the diagnosis of GH deficiency (GHD) in adults was only considered as a marker of hypothalamo-pituitary disease. GHD in adults is now recognized as a specific clinical syndrome associated with a cluster of cardiovascular risk factors such as altered body composition with increased body fat, insulin resistance, adverse lipid profile, reduced physical performance …
Grigorios Rombopoulos, Magdalini Hatzikou, Dimitra Latsou, John Yfantopoulos
OBJECTIVE: To estimate the impact of hypoglycemia on the Quality of Life (QoL) and its prevalence in patients with type 2 diabetes mellitus (T2DM) in Greece. DESIGN: A cross-sectional epidemiological study was conducted in 6631 patients with T2DM …
Lisanne Smans, Eef Lentjes, Ad Hermus, Pierre Zelissen
OBJECTIVE: Patients with Addison’s disease require lifelong treatment with glucocorticoids. At present, no glucocorticoid replacement therapy (GRT) can exactly mimic normal physiology. As a consequence, under- and especially overtreatment can occur. Suboptimal GRT may lead to various side effects …
Hidetoshi Ikeda, Masataka Kudo
Objective: We evaluated the long-term effects of growth hormone (GH) on markers of quality of life, glucose metabolism, and lipid metabolism to validate the adequacy of long-term GH replacement therapy for adult GH deficiency (AGHD). Design: Eighty-three of 100 sequentially followed patients who received GH therapy …